孔女士在投资银行和保健业有丰富经验。 她曾于在纽约的Allegiance Capital工作,在那里她曾参与多元化的并购交易。她还是罗伯茨的伙伴,在纽约的投资银行与生命科学重点那里,她是为出售方负责资产评估与交易分析的,她也为几个医疗器械公司从事私人股本配售。她在投资银行工作之前, 就担任了出售方投资学研究方面的股票研究分析员，这个投资银行被《商业周刊》评为表现最佳的独立研究公司。她负责为制药界及中间公司盖章。此外,孔女士在生物资源开发方面与临床医学有丰富而宝贵的经验, 她花费多年在人类基因组计划和安德森癌症中心从事科学研究。孔女士也在医学院毕业后完成住院医师培训。
Ms. Kong has extensive experience in the investment banking and healthcare industry. She worked for Allegiance Capital in New York, where she was involved in diverse Mergers and Acquisition transactions. She also worked for Roberts Mitani Partner, a New York based investment bank with life sciences focuses, where she was responsible for performing valuation and transaction analysis for sell-side mandates. She was also engaged in private equity placement for several medical devices firms. Before her work in investment banking, Ms. Kong worked as a sell-side equity research analyst for Investology Research, which was top-ranked as one of the best performing independent research firms by Business Week. She was responsible for the pharmaceutical sector and covered middle cap firms. In addition, Ms. Kong has extensive and valuable experience in the biotech sector and clinical medicine. She spent years on scientific research in the Human Genome Project and M.D. Anderson Cancer Center. Ms. Kong also completed her residency training after medical school.
Ms. Kong has extensive experience in the investment banking and healthcare industry. She worked for Allegiance Capital in New York, where she was involved in diverse Mergers and Acquisition transactions. She also worked for Roberts Mitani Partner, a New York based investment bank with life sciences focuses, where she was responsible for performing valuation and transaction analysis for sell-side mandates. She was also engaged in private equity placement for several medical devices firms. Before her work in investment banking, Ms. Kong worked as a sell-side equity research analyst for Investology Research, which was top-ranked as one of the best performing independent research firms by Business Week. She was responsible for the pharmaceutical sector and covered middle cap firms. In addition, Ms. Kong has extensive and valuable experience in the biotech sector and clinical medicine. She spent years on scientific research in the Human Genome Project and M.D. Anderson Cancer Center. Ms. Kong also completed her residency training after medical school.